These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28786282)

  • 21. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
    Hsiao FY; Huang WF; Chen YM; Wen YW; Kao YH; Chen LK; Tsai YW
    Clin Ther; 2011 Nov; 33(11):1659-67. PubMed ID: 22018450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort.
    Won SH; Ahn S; Ji E; Park JW; Kim JK; Lee YK
    J Korean Med Sci; 2020 Jun; 35(25):e193. PubMed ID: 32597040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Subtrochanteric pathological fracture on bisphosphonates].
    Mathonet PY; Willems S; Ciornohac JF
    Rev Med Liege; 2018 Feb; 73(2):56-60. PubMed ID: 29517866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
    Abrahamsen B; Eiken P; Eastell R
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5258-65. PubMed ID: 20843943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical diaphyseal femoral fractures: Considerations on surgical technique.
    Spinelli MS; Marini E; Daolio PA; Piccioli A
    Injury; 2019 Jul; 50 Suppl 2():S65-S69. PubMed ID: 30782394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance.
    Lloyd AA; Gludovatz B; Riedel C; Luengo EA; Saiyed R; Marty E; Lorich DG; Lane JM; Ritchie RO; Busse B; Donnelly E
    Proc Natl Acad Sci U S A; 2017 Aug; 114(33):8722-8727. PubMed ID: 28760963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A; Blanco R
    Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture.
    Jiang SY; Kaufman DJ; Chien BY; Longoria M; Shachter R; Bishop JA
    Clin Orthop Relat Res; 2019 Mar; 477(3):480-490. PubMed ID: 30394950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy.
    Murray JC; Audet MC; Bédard M; Michou L
    Osteoporos Int; 2016 Feb; 27(2):833-6. PubMed ID: 26556740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
    Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
    J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiographic Changes and Fracture in Patients Having Received Bisphosphonate Therapy for ≥ 5 Years at a Single Institution.
    Ernat J; Song D; Fazio M; Lindell K; Orchowski J
    Mil Med; 2015 Dec; 180(12):1214-8. PubMed ID: 26633664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy.
    Lim HS; Kim CK; Park YS; Moon YW; Lim SJ; Kim SM
    J Bone Joint Surg Am; 2016 Dec; 98(23):1978-1987. PubMed ID: 27926679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
    Clout A; Narayanasamy N; Harris I
    J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical fractures of the femur related to prolonged treatment with bisphosphonates for osteoporosis.
    Rosenthal Y; Arami A; Kosashvili Y; Cohen N; Sidon E; Velkes S
    Isr Med Assoc J; 2014 Feb; 16(2):78-82. PubMed ID: 24645224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonate-induced atypical subtrochanteric femoral fracture.
    Vaishya R; Vaish A; Nadeem A
    BMJ Case Rep; 2013 Nov; 2013():. PubMed ID: 24287483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.
    Safford MM; Barasch A; Curtis JR; Outman R; Saag K
    J Clin Rheumatol; 2014 Oct; 20(7):357-62. PubMed ID: 25275761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial.
    Adachi JD; Lyles K; Boonen S; Colón-Emeric C; Hyldstrup L; Nordsletten L; Pieper C; Recknor C; Su G; Bucci-Rechtweg C; Magaziner J
    Calcif Tissue Int; 2011 Dec; 89(6):427-33. PubMed ID: 22038744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonate-related subtrochanteric femoral fractures.
    Gunawardena I; Baxter M; Rasekh Y
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):194-8. PubMed ID: 21470918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management.
    Blum L; Cummings K; Goulet JA; Perdue AM; Mauffrey C; Hake ME
    Eur J Orthop Surg Traumatol; 2016 May; 26(4):371-7. PubMed ID: 26943872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.